CASI Pharmaceuticals, Inc. (CASIF)
OTCMKTS · Delayed Price · Currency is USD
0.1288
+0.0088 (7.33%)
At close: Aug 11, 2026
CASI Pharmaceuticals Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -48.06 | -39.26 | -26.26 | -40.26 | -35.84 |
Depreciation & Amortization | 2.29 | 3.45 | 4.73 | 3.61 | 3.1 |
Stock-Based Compensation | 2.99 | 1.31 | 7.22 | 7.01 | 7.77 |
Other Adjustments | 3.52 | 4.51 | 2.16 | 15.2 | 1.35 |
Change in Receivables | 11.25 | -5.79 | 3.42 | -3.17 | -5.16 |
Changes in Inventories | 2.51 | 5.83 | -9.74 | -4.23 | -0.55 |
Changes in Accounts Payable | -1.66 | -1.72 | 1.15 | 1.07 | 1.49 |
Changes in Accrued Expenses | 6.39 | 1.55 | -0.88 | -0.91 | 2.35 |
Changes in Income Taxes Payable | - | - | -1.89 | 1.98 | - |
Changes in Unearned Revenue | - | - | - | - | -0.05 |
Changes in Other Operating Activities | 0.01 | 0.91 | 0.11 | -1.38 | -1.3 |
Operating Cash Flow | -20.75 | -29.22 | -19.97 | -21.09 | -26.84 |
Operating Cash Flow Growth | - | - | - | - | - |
Capital Expenditures | -0.02 | -0.22 | -0.2 | -5.61 | -8.95 |
Sale of Property, Plant & Equipment | - | - | - | 0.14 | 0.01 |
Purchases of Intangible Assets | -0.01 | -0.02 | -2.04 | - | -6.56 |
Proceeds from Sale of Intangible Assets | - | 0.5 | - | - | - |
Purchases of Investments | -1.62 | -2.78 | -51.75 | -7.43 | -5.85 |
Proceeds from Sale of Investments | 2.6 | 13.76 | 44.32 | 37.62 | 0.17 |
Other Investing Activities | - | - | - | 6.44 | 0.47 |
Investing Cash Flow | 0.95 | 11.24 | -9.67 | 31.16 | -20.69 |
Long-Term Debt Issued | 6 | - | - | 4 | 0.71 |
Long-Term Debt Repaid | - | - | - | -4 | -1.55 |
Net Long-Term Debt Issued (Repaid) | 6 | - | - | 0 | -0.84 |
Issuance of Common Stock | 5.93 | 17.11 | 0.11 | - | 32.5 |
Repurchase of Common Stock | - | - | -0.28 | -3.27 | - |
Net Common Stock Issued (Repurchased) | 5.93 | 17.11 | -0.17 | -3.27 | 32.5 |
Other Financing Activities | -0.68 | -1.68 | -0.74 | - | -2.02 |
Financing Cash Flow | 11.25 | 15.43 | -0.91 | -3.27 | 29.64 |
Foreign Exchange Rate Adjustments | 0.71 | -1.07 | 0.52 | 1.6 | -0.47 |
Net Cash Flow | -7.84 | -3.62 | -30.03 | 8.41 | -18.36 |
Free Cash Flow | -20.77 | -29.45 | -20.17 | -26.7 | -35.79 |
Free Cash Flow Growth | - | - | - | - | - |
FCF Margin | -100.28% | -103.19% | -59.54% | -61.94% | -118.63% |
Free Cash Flow Per Share | -1.12 | -1.92 | -1.51 | -1.96 | -2.63 |
Levered Free Cash Flow | -32.53 | -29.47 | -33.68 | -46.5 | -41.4 |
Unlevered Free Cash Flow | -35.48 | -29.83 | -31.72 | -41.31 | -45.75 |